Answers are grounded in this paper and cite their sources.
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.
No takes yet. Share an insight, caveat, or question.
Lemoine et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: